CY1105805T1 - Νεος σχηματισμος - Google Patents

Νεος σχηματισμος

Info

Publication number
CY1105805T1
CY1105805T1 CY20061101705T CY061101705T CY1105805T1 CY 1105805 T1 CY1105805 T1 CY 1105805T1 CY 20061101705 T CY20061101705 T CY 20061101705T CY 061101705 T CY061101705 T CY 061101705T CY 1105805 T1 CY1105805 T1 CY 1105805T1
Authority
CY
Cyprus
Prior art keywords
new formation
pharmaceutical composition
freeze drying
nucleotide analog
glass forming
Prior art date
Application number
CY20061101705T
Other languages
Greek (el)
English (en)
Inventor
Joanne Broadhead
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105805(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1105805T1 publication Critical patent/CY1105805T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20061101705T 1997-07-11 2006-11-27 Νεος σχηματισμος CY1105805T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
PCT/SE1998/001287 WO1999002542A1 (en) 1997-07-11 1998-06-29 New formulation

Publications (1)

Publication Number Publication Date
CY1105805T1 true CY1105805T1 (el) 2011-02-02

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101705T CY1105805T1 (el) 1997-07-11 2006-11-27 Νεος σχηματισμος

Country Status (35)

Country Link
US (1) US6130208A (cg-RX-API-DMAC10.html)
EP (1) EP1000079B1 (cg-RX-API-DMAC10.html)
JP (1) JP4950380B2 (cg-RX-API-DMAC10.html)
KR (1) KR100786654B1 (cg-RX-API-DMAC10.html)
CN (2) CN1864696A (cg-RX-API-DMAC10.html)
AR (1) AR013157A1 (cg-RX-API-DMAC10.html)
AT (1) ATE340801T1 (cg-RX-API-DMAC10.html)
AU (1) AU8362598A (cg-RX-API-DMAC10.html)
BR (1) BR9810703A (cg-RX-API-DMAC10.html)
CA (1) CA2295628C (cg-RX-API-DMAC10.html)
CY (1) CY1105805T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ298110B6 (cg-RX-API-DMAC10.html)
DE (1) DE69836023T2 (cg-RX-API-DMAC10.html)
DK (1) DK1000079T3 (cg-RX-API-DMAC10.html)
EE (1) EE04119B1 (cg-RX-API-DMAC10.html)
ES (1) ES2273425T3 (cg-RX-API-DMAC10.html)
HU (1) HU226489B1 (cg-RX-API-DMAC10.html)
ID (1) ID24716A (cg-RX-API-DMAC10.html)
IL (2) IL133868A0 (cg-RX-API-DMAC10.html)
IS (1) IS2439B (cg-RX-API-DMAC10.html)
MY (1) MY116421A (cg-RX-API-DMAC10.html)
NO (1) NO329918B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ502073A (cg-RX-API-DMAC10.html)
PL (1) PL192768B1 (cg-RX-API-DMAC10.html)
PT (1) PT1000079E (cg-RX-API-DMAC10.html)
RU (1) RU2216330C2 (cg-RX-API-DMAC10.html)
SA (1) SA98190328B1 (cg-RX-API-DMAC10.html)
SE (1) SE9702680D0 (cg-RX-API-DMAC10.html)
SI (1) SI1000079T1 (cg-RX-API-DMAC10.html)
SK (1) SK285766B6 (cg-RX-API-DMAC10.html)
TR (1) TR200000006T2 (cg-RX-API-DMAC10.html)
TW (1) TW585764B (cg-RX-API-DMAC10.html)
UA (1) UA65576C2 (cg-RX-API-DMAC10.html)
WO (1) WO1999002542A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA985669B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038647A1 (ja) * 2004-10-05 2006-04-13 Asahi Kasei Pharma Corporation 補酵素の安定化方法およびその組成物
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 3−(ビアリールオキシ)プロピオン酸誘導体
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2498731B1 (en) 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
WO2012079035A1 (en) * 2010-12-10 2012-06-14 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
AU2012214396B2 (en) 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
DK2744424T3 (en) 2011-08-17 2018-01-22 Samuel Shiber Adaptively rotating catheter to open clogged vessels in the body
EP3978002A1 (en) 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
PE20221170A1 (es) 2015-01-14 2022-07-25 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
ES3067885T3 (en) 2017-06-23 2026-05-26 Chiesi Farm Spa Cangrelor for the treatment and/or prevention of shunt or stent thrombosis
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ucb製藥有限公司 吡啶基及吡基-(氮)吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (cg-RX-API-DMAC10.html) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社 ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
DE69406649T2 (de) * 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge
CZ306394A3 (en) * 1993-12-14 1995-08-16 Lilly Co Eli Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
WO1996040265A1 (en) * 1995-06-07 1996-12-19 The Regents Of The University Of California Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku

Also Published As

Publication number Publication date
DK1000079T3 (da) 2006-11-20
SE9702680D0 (sv) 1997-07-11
TR200000006T2 (tr) 2000-07-21
CA2295628C (en) 2008-07-29
DE69836023T2 (de) 2007-04-12
SK285766B6 (sk) 2007-07-06
UA65576C2 (uk) 2004-04-15
ATE340801T1 (de) 2006-10-15
CZ200083A3 (cs) 2000-06-14
HK1026429A1 (en) 2000-12-15
AR013157A1 (es) 2000-12-13
HUP0002622A3 (en) 2002-04-29
EE200000022A (et) 2000-10-16
IS5331A (is) 1999-12-30
KR100786654B1 (ko) 2007-12-21
TW585764B (en) 2004-05-01
IL133868A (en) 2010-05-17
RU2216330C2 (ru) 2003-11-20
KR20010021647A (ko) 2001-03-15
EP1000079B1 (en) 2006-09-27
WO1999002542A1 (en) 1999-01-21
EE04119B1 (et) 2003-08-15
AU8362598A (en) 1999-02-08
PL192768B1 (pl) 2006-12-29
CA2295628A1 (en) 1999-01-21
US6130208A (en) 2000-10-10
SK183699A3 (en) 2000-07-11
EP1000079A1 (en) 2000-05-17
IL133868A0 (en) 2001-04-30
NZ502073A (en) 2001-09-28
MY116421A (en) 2004-01-31
CN1263533A (zh) 2000-08-16
SA98190328B1 (ar) 2006-08-15
PL337970A1 (en) 2000-09-11
NO20000123L (no) 2000-03-03
BR9810703A (pt) 2000-08-08
HU226489B1 (en) 2009-03-02
JP4950380B2 (ja) 2012-06-13
NO329918B1 (no) 2011-01-24
ES2273425T3 (es) 2007-05-01
JP2001509512A (ja) 2001-07-24
ID24716A (id) 2000-08-03
NO20000123D0 (no) 2000-01-10
CN1864696A (zh) 2006-11-22
ZA985669B (en) 1999-01-11
HUP0002622A2 (hu) 2001-05-28
CZ298110B6 (cs) 2007-06-27
DE69836023D1 (de) 2006-11-09
PT1000079E (pt) 2006-12-29
SI1000079T1 (sl) 2007-08-31
IS2439B (is) 2008-11-15

Similar Documents

Publication Publication Date Title
DE69708120D1 (de) Laser-absorbierende, lichtbleichbare zusammensetzungen
BR9913138B1 (pt) Derivado de quinolin-2-ona substituído com alquinila e composição farcêutica contendo o mesmo
ID27415A (id) Komposisi farmaseutik
ID16420A (id) Komposisi farmasi baru dengan efek anastesia
ATE228357T1 (de) Nukleotid-analoge zusammensetzung
IS4974A (is) Lyfjasamsetning á þrýstingsúðaformi
PT941998E (pt) Antibioticos macrolidos do tipo 3,6-cetal
ID17774A (id) Komposisi farmasi antitrombosis
AR016981A2 (es) Polipeptidos sinteticos
DE69731747D1 (de) Peptid derivate
ID27201A (id) Komposisi farmasi
FR2746317B1 (fr) Nouvelles compositions antitumorales
DE69700310D1 (de) Rostschutzzusammensetzung
MY116421A (en) New formulation
DE69810602D1 (de) Hochtransparentes,farbpigmentiertes material mit hohem molekulargewicht
EE03857B1 (et) Ravimkoostised külmkuivatamiseks
ID18698A (id) Komposisi farmasi
PT1039908E (pt) Composicao de dispersao molecular com biodisponibilidade melhorada
NL1005675A1 (nl) Polytriazinederivaten-bevattende polyalkylpiperidinyloxy- of polyalkylpiperidinylaminogroepen.
DE69911578D1 (de) Lumineszentes material
FR2747686B1 (fr) Materiau fluorescent
ITMI962628A0 (it) Composizione farmaceutica
ID20352A (id) Bahan herbisida 3,5-difluoropiridin
ES1034081Y (es) Portamechas para expositores de peluqueria.
ID23531A (id) Komposisi farmasi